|
Video: What is a Stock Split?
|
|
Agenus is a clinical-stage immuno-oncology (I-O) company engaged in the development of a pipeline of immune checkpoint antibodies, adoptive cell therapies and neoantigen cancer vaccines, to fight cancer and infections. Co.'s antibody candidates are balstilimab (an anti-PD-1 antibody) and zalifrelimab (an anti-CTLA-4 antibody), which are in Phase 2 trials as both a monotherapy (balstilimab) and combination therapy (balstilimab/zalifrelimab) for treatment of patients with second-line cervical cancer. Co. is also developing an anti-CTLA-4 antibody, botensilimab (also known as AGEN1181), which is designed to improve the magnitude of responses to first-generation anti-CTLA-4 molecules. According to our AGEN split history records, Agenus has had 2 splits. | |
|
Agenus (AGEN) has 2 splits in our AGEN split history database. The first split for AGEN took place on April 26, 2023. This was a 1019 for 1000 split, meaning for each 1000 shares of AGEN owned pre-split, the shareholder now owned 1019 shares. For example, a 1000 share position pre-split, became a 1019 share position following the split. AGEN's second split took place on April 12, 2024. This was a 1 for 20 reverse split, meaning for each 20 shares of AGEN owned pre-split, the shareholder now owned 1 share. For example, a 1019 share position pre-split, became a 50.95 share position following the split.
When a company such as Agenus splits its shares, the market capitalization before and after the split takes place remains stable, meaning the shareholder now owns more shares but each are valued at a lower price per share. Often, however, a lower priced stock on a per-share basis can attract a wider range of buyers. If that increased demand causes the share price to appreciate, then the total market capitalization rises post-split. This does not always happen, however, often depending on the underlying fundamentals of the business. When a company such as Agenus conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the AGEN split history from start to finish, an original position size of 1000 shares would have turned into 50.95 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Agenus shares, starting with a $10,000 purchase of AGEN, presented on a split-history-adjusted basis factoring in the complete AGEN split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
04/22/2014 |
|
End date: |
04/19/2024 |
|
Start price/share: |
$53.40 |
|
End price/share: |
$5.31 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-90.06% |
|
Average Annual Total Return: |
-20.61% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$994.62 |
|
Years: |
10.00 |
|
|
|
Date |
Ratio |
04/26/2023 | 1019 for 1000 | 04/12/2024 | 1 for 20 |
|
|